A new report, "Friedreich Ataxia - Global Clinical Trials Review, 2024," offers a detailed analysis of the clinical trial landscape for Friedreich Ataxia, a rare genetic disease affecting the nervous system. The report, available from ResearchAndMarkets.com, provides an overview of trial numbers, average enrollment, and geographical distribution, offering valuable insights for researchers, pharmaceutical companies, and investors.
The report covers clinical trials across various regions, including the G7 and E7 countries, and analyzes data based on trial phase, status, end-point status, and sponsor type. It also identifies prominent drugs currently under investigation for Friedreich Ataxia.
Key Findings and Scope
The analysis includes a snapshot of the global clinical trials landscape, providing top-level data related to clinical trials by region, country, trial status, trial phase, sponsor type, and end-point status. It reviews top companies involved in Friedreich Ataxia research and lists all trials pertaining to each company, including trial title, phase, and status.
Furthermore, the report identifies unaccomplished trials (terminated, suspended, and withdrawn) and the reasons for their discontinuation. Enrollment trends over the past five years and the latest news from the past three months are also included.
Strategic Insights and Opportunities
The report assists in formulating key business strategies related to investment and helps identify optimal locations for conducting clinical trials, potentially saving time and costs. It provides a top-level analysis of the global clinical trials market, aiding in the identification of key business opportunities and supporting an understanding of trial count and enrollment trends by country.
Additionally, the report aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials, facilitating clinical trial assessment of the indication on a global, regional, and country level.
Companies Involved
Several prominent pharmaceutical and biotechnology companies are actively involved in Friedreich Ataxia clinical trials. These include:
- Biogen Inc
- Santhera Pharmaceuticals Holding AG
- PTC Therapeutics Inc
- Clinilabs Inc
- Larimar Therapeutics Inc
- Design Therapeutics Inc
- Ixchel Pharma LLC
- Neurocrine Biosciences Inc
- Pfizer Inc
- Takeda Pharmaceutical Co Ltd
